Reflection Paper for Laboratories That Perform the Analysis or Evaluation of Clinical Trial Samples
The EMA reflection paper setting out the quality-system expectations for laboratories that analyse or evaluate samples from clinical trials, bridging the gap between GCP (which governs the trial) and GLP (which governs non-clinical safety studies). Adopted 28 February 2012, it is the European inspection benchmark for clinical-trial laboratories.
What this does not cover
stated in the document's own scope- Applies to laboratories analysing or evaluating clinical-trial samples; the conduct of the trial itself is governed by GCP (ICH E6).
- Interprets how GCP expectations apply in a laboratory; it does not create a GLP-style statutory regime for trial labs.
- Is EU inspection guidance; US clinical-laboratory certification is governed separately by CLIA under 42 CFR Part 493.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
This EMA reflection paper sets out the quality-system expectations for laboratories that perform the analysis or evaluation of samples taken during clinical trials. It fills a recognised gap: the trial itself is governed by Good Clinical Practice, while Good Laboratory Practice governs non-clinical safety studies, leaving the clinical-trial laboratory between the two. The paper describes how the data-quality principles of GCP should be applied in a laboratory setting — organisation and personnel, facilities and equipment, method validation, sample handling and traceability, documentation, and the responsibilities shared between the sponsor and the laboratory — and it is widely referenced as the European quality-system benchmark for bioanalytical, biomarker, central, and specialty laboratories supporting trials.
Scope & applicability
Laboratories analysing or evaluating clinical-trial samples (bioanalytical, biomarker, central, and specialty labs) supporting EU trials. It interprets how GCP data-quality expectations apply to a laboratory setting rather than establishing a new GLP-style regime.
Legal basis & how it acquires force
The document is a reflection paper adopted by the EMA GCP Inspectors Working Group (reference EMA/INS/GCP/532137/2010), adopted on 28 February 2012. As a reflection paper it is interpretive guidance rather than legislation; it articulates the quality-system expectations the EMA GCP Inspectors Working Group set out for clinical-trial laboratories operating under the EU clinical-trials framework.
Document structure
| Part | Covers |
|---|---|
| Organisation and personnel | Quality-system responsibilities, training, and organisation of the laboratory supporting a trial |
| Facilities and equipment | Suitable facilities, qualified equipment, and their control and maintenance |
| Methods and sample handling | Method validation, controlled and traceable handling of clinical-trial samples, and analysis |
| Documentation and records | Records that make each result attributable and the analysis reconstructable |
| Roles and responsibilities | The interface between the sponsor, the trial, and the laboratory |
Key requirements
- A quality system covering organisation, personnel, facilities, and equipment for trial-sample analysis
- Validated methods and controlled, traceable handling of clinical-trial samples
- Documentation and records that make each result attributable and reconstructable
- Defined responsibilities at the interface between the sponsor, the trial, and the laboratory
International alignment
The reflection paper bridges GCP (which governs the conduct of the trial) and GLP (which governs non-clinical safety studies), and it aligns conceptually with the WHO GCLP handbook and with laboratory-competence standards such as ISO 15189 and ISO/IEC 17025. In the United States the comparable operational layer for laboratories testing human specimens is CLIA (42 CFR Part 493), a different legal instrument with overlapping quality aims.
EMA/INS/GCP/532137/2010: frequently asked questions
Quick answers to common questions about EMA/INS/GCP/532137/2010.
Why does a clinical-trial laboratory need this reflection paper?
Because trial labs sit between GCP (which governs the trial) and GLP (which governs non-clinical safety studies); the paper describes how GCP data-quality expectations should be applied in the laboratory setting.
Is the reflection paper legally binding?
It is interpretive guidance rather than legislation; it articulates the quality-system expectations the EMA GCP Inspectors Working Group set out for clinical-trial laboratories.
When was it adopted?
It was adopted by the EMA GCP Inspectors Working Group on 28 February 2012 under reference EMA/INS/GCP/532137/2010.